Suggestions
Kevin Judice
CEO, DiCE Molecules
Professional Background
Kevin Judice is a seasoned executive in the biotechnology sector with over 25 years of extensive experience. As the CEO and co-founder of DiCE Molecules, Kevin has been instrumental in driving innovative approaches to drug discovery and development, leveraging the power of molecular engineering to address critical healthcare challenges. Under his leadership, DiCE Molecules has emerged as a frontrunner in the biotech industry, dedicated to creating therapies that can improve the lives of patients globally.
Before establishing DiCE Molecules, Kevin showcased his entrepreneurial spirit and scientific acumen as a co-founder and Acting Chief Scientific Officer (CSO) at Cidara Therapeutics from 2012 to 2014. His leadership helped shape the company's strategic direction, leading to significant advances in their portfolio of therapeutics aimed at treating infectious diseases.
Prior to Cidara, Kevin was a founder, CEO, and CSO at Achaogen, where he played a pivotal role in leading the company through its early stages, culminating in its initial public offering. Achaogen's mission to develop innovative antibiotics underscored Kevin's commitment to addressing the growing concerns of antibiotic resistance. Earlier in his career, he contributed to the groundbreaking work at Theravance, where as one of the first employees, he played an instrumental role in the company’s vision and success.
Kevin's journey in biotech began at Genentech, where he held several key roles, including Scientist and Senior Director of Medicinal Chemistry. His tenacity and proficiency in chemistry helped propel Genentech toward new heights, establishing the company as a leader in therapeutics development. His extensive background reflects a blend of scientific expertise and strategic insight that is paramount in today’s rapidly evolving biotech landscape.
Education and Achievements
Kevin's academic credentials are as impressive as his professional career. He embarked on his academic journey at Texas A&M University, where he earned a Bachelor of Science (BS) degree in Chemistry. Building on this foundation, he pursued a Ph.D. in Organic Chemistry at UCLA, a testament to his profound commitment to understanding complex chemical processes.
Following his doctoral studies, Kevin expanded his specialization by completing a post-doctoral fellowship in Molecular Biology and Protein Engineering at the prestigious University of California, Berkeley. This phase of his education was crucial in developing expertise in the molecular mechanisms that underpin drug development, enabling him to lead biotech initiatives with a blend of innovative thought and solid scientific grounding.
Notable Achievements
Kevin Judice has made impactful contributions to the biotechnology field, particularly in drug discovery and molecular engineering. His work has consistently focused on developing innovative solutions that tackle key medical challenges, particularly in treating infectious diseases. The companies he has co-founded and led have been recognized within the industry for their revolutionary approaches to healthcare.
His strategic vision has led to notable advances in therapeutic development, including contributions to antibiotic therapy, which is crucial as the world faces increasing antibiotic resistance. Kevin's consultative role on the Scientific Advisory Board at Calibr at Scripps Research further cements his reputation as a thought leader, where he provides guidance on innovative science and its potential applications in biomedicine. Moreover, as a Henry Crown Fellow at The Aspen Institute, Kevin engaged with fellow leaders to foster discussion and collaboration on pressing global issues, enhancing his leadership profile and network within the scientific community. His vast experience and contributions position him as a key figure in reshaping the future of biotechnology.
